Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome

Haipeng Zhu, Gary E. Grajales-Reyes, Vivianette Alicea-Vázquez, Jose G. Grajales-Reyes, Ka Reisha Robinson, Peter Pytel, Carlos A. Báez-Pagán, Jose A. Lasalde-Dominicci, Christopher M. Gomez

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


The slow-channel congenital myasthenic syndrome (SCS) is an inherited neurodegenerative disease that caused mutations in the acetylcholine receptor (AChR) affecting neuromuscular transmission. Leaky AChRs lead to Ca2+ overload and degeneration of the neuromuscular junction (NMJ) attributed to activation of cysteine proteases and apoptotic changes of synaptic nuclei. Here we use transgenic mouse models expressing two different mutations found in SCS to demonstrate that inhibition of prolonged opening of mutant AChRs using fluoxetine not only improves motor performance and neuromuscular transmission but also prevents Ca2+ overload, the activation of cysteine proteases, calpain, caspase-3 and 9 at endplates, and as a consequence, reduces subsynaptic DNA damage at endplates, suggesting a long term benefit to therapy. These studies suggest that prolonged treatment of SCS patients with open ion channel blockers that preferentially block mutant AChRs is neuroprotective.

Original languageEnglish
Pages (from-to)88-94
Number of pages7
JournalExperimental Neurology
StatePublished - Jun 13 2015


  • Acetylcholine receptor
  • Ca2+ overload
  • Fluoxetine
  • Ion channel blockers
  • Mutation
  • Neurodegenerative disease
  • Neuromuscular junction
  • Neuromuscular transmission
  • Neuroprotective
  • Slow-channel congenital myasthenic syndrome
  • Subsynaptic DNA damage


Dive into the research topics of 'Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome'. Together they form a unique fingerprint.

Cite this